Fig. 3: Direct detection of SARS-CoV-2 RNA in plasma EVs.
From: Liposome-mediated detection of SARS-CoV-2 RNA-positive extracellular vesicles in plasma
a, CRISPR-FDS liposome assay signals detected with EVs isolated from 293F cells stably transfected with a SARS-CoV-2 N gene expression vector or the empty expression vector. The data represent the mean ± s.d. of three replicates. b, CRISPR-FDS liposome assay kinetics for EVs captured from 100 µl plasma aliquots of individuals diagnosed with and without COVID-19 (EVpos and EVneg samples, respectively) upon incubation with CRISPR-FDS reagent-loaded liposomes with or without PEG, or with free CRISPR-FDS reagents. c, CRISPR-FDS liposome assay signals detected from 100 µl plasma aliquots from 20 adults with COVID-19 and 10 adults without COVID-19, as diagnosed by nasal swab RT–qPCR results. d, CRISPR-FDS liposome assay signals detected from plasma samples from six patients diagnosed with COVID-19 but who were diagnosed COVID-19-negative by their nasal swab samples (A40–A45), a healthy donor (HD) and a positive control (whose nasal swab samples were RT–qPCR-positive). Symptoms, imaging data, molecular tests results and treatment responses of patients A40–A45 are summarized in the adjacent table. The data represent the mean ± s.d. of three replicates. CT, computed tomography; NA, not applicable. ****P < 0.0001.
